GlassScriptPhysician profile
Kristen G Robinson
NPI 1811207343
$3,573.82
in general payments reported to CMS, 2019-2025
33 companies · $657 in 2025
The $657 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $641 · 2022: $788 · 2023: $1,055 · 2024: $433 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.27 |
| Education | $144.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $647.68 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $393.72 | 2021-2025 | Trintellix |
| Sumitomo Pharma America, INC. | $348.03 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $276.48 | 2023-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $198.97 | 2023-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $192.02 | 2023-2024 | Wegovy |
| Aspira Women'S Health INC | $172.39 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $152.51 | 2021-2023 | Contrave |
| Sage Therapeutics, LLC | $145.52 | 2021-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $99.18 | 2021-2023 | Phexxi |
| Pfizer INC. | $83.72 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.83 | 2021-2023 | |
| Myriad Women'S Health, INC. | $80.37 | 2023 | Myrisk |
| Millicent US INC | $69.32 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Axsome Therapeutics, INC. | $66.28 | 2023-2025 | Auvelity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $63.73 | 2022 | |
| Urovant Sciences INC | $63.30 | 2022 | |
| Mayne Pharma Commercial LLC | $59.71 | 2023 | |
| Daiichi Sankyo INC. | $57.52 | 2021-2022 | |
| Shield Therapeutics INC | $43.82 | 2024-2025 | |
| Scynexis, INC. | $32.96 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $30.61 | 2024-2025 | |
| Davol INC. | $28.38 | 2024 | Arista Ah Flexitip |
| Amgen INC. | $26.75 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $24.23 | 2024 | |
| Vivus LLC | $23.65 | 2024 | Qsymia |
| Pacira Pharmaceuticals Incorporated | $19.38 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.99 | 2023 | Xifaxan |
| Avion Pharmaceuticals | $17.95 | 2023 | Balcoltra |
| Axonics, INC. | $16.71 | 2023 | Axonics |
| Virtus Pharmaceuticals LLC | $13.90 | 2021 | |
| Lupin INC. | $13.09 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.